Troy A. Ignelzi - 15 Feb 2022 Form 4 Insider Report for Karuna Therapeutics, Inc.

Role: Chief Financial Officer
Signature: /s/ Troy Ignelzi
Issuer symbol: N/A
Transactions as of: 15 Feb 2022
Net transactions value: -$152,910
Form type: 4
Filing time: 17 Feb 2022, 16:21:04 UTC
Previous filing: 06 Jan 2022
Next filing: 21 Apr 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	KRTX	Common Stock	Options Exercise	$13,800	+1,500	+6%	$9.20^*	26,470	15 Feb 2022	Direct
transaction	KRTX	Common Stock	Sale	$166,710	-1,500	-5.7%	$111.14	24,970	15 Feb 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	KRTX	Option (right to buy)	Options Exercise	$0	-1,500	-0.94%	$0.000000	158,856	15 Feb 2022	Common Stock	1,500	$9.20	Direct	F2
transaction	KRTX	Option (right to buy)	Award	$0	+48,500		$0.000000	48,500	16 Feb 2022	Common Stock	48,500	$111.97	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 1, 2022.
F2	This option vested as to 25% of the shares on the first anniversary of the vesting commencement date of March 1, 2019, with additional vesting as to 12.5% of the shares underlying the option award on each six month period thereafter.
F3	25% of the options shall vest on February 16, 2023, and the remaining options shall vest in twelve equal three-month installments over the following three years, subject to continued service through such dates.